Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Neurocrine Biosciences, Inc. NBIX

Set alert

Price alert · NBIX

All alert types
145.35 USD -0.75 -0.51%

At close

156.00 +10.65 +7.33%

Pre-market · Nov 3, 7:30 AM ET

Bid
145.33 × 1
Ask
145.44 × 1
143.75 Day range 147.57
122.14 52-week range 186.12
YTD
+2.48%
1 year
+2.39%
Open
145.70
Prev close
146.10
Mkt cap
14.77B
Vol
2.02M
Avg vol
1.25M
EPS
6.74
P/E
21.57
Div yield
0.00%
More statistics
Low
143.75
High
147.57
Forward P/E
12.14
Beta
0.33
Short ratio
4.41
Inst. own
104.46%
Dividend
0.00
Ex-div date
Dec 28, 1995
Earnings
Feb 10, 2027
50-d avg
146.63
200-d avg
147.38
1y target
206.22

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Sep 3, 2026Rating: Citigroup · Buy → Buy
  • Sep 8, 2026Rating: RBC Capital · Outperform → Outperform
  • Sep 11, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
  • Sep 29, 2026Rating: UBS · Buy → Buy
  • Oct 12, 2026Rating: BMO Capital · Market Perform → Market Perform
  • Oct 16, 2026Rating: Needham · Buy → Buy
  • Nov 2, 2026Earnings: 3.29; estimate 1.91; surprise 72.25%
Signals (10)
NameDateAgo
SMA: BullishOct 22, 20261 week ago
MACD: Buy SignalOct 20, 20261 week ago
MACD: Sell SignalOct 14, 20262 weeks ago
MACD: Buy SignalOct 2, 20261 month ago
RSI: OversoldSep 29, 20261 month ago
RSI: OversoldSep 22, 20261 month ago
MACD: Sell SignalSep 16, 20261 month ago
SMA: BearishSep 15, 20261 month ago
SMA: BullishSep 14, 20261 month ago
MACD: Buy SignalAug 27, 20262 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 206.22 +41.9% upside
Target (low)
150.00
Target (mean)
206.22
Target (high)
253.00
Ratings (0m) 29 25 buy · 4 hold · 0 sell
  • Strong buy4
  • Buy21
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 29
  • 1 month ago 29
  • 2 months ago 28

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

NBIX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter2.752.07 – 3.332.17+26.5%1.04B+31.3%17
Next quarter2.812.13 – 3.651.88+49.4%1.09B+34.7%14
Current year10.248.98 – 11.406.39+60.3%3.90B+36.5%17
Next year11.978.37 – 16.0610.24+16.9%4.55B+16.6%15

Upgrades and downgrades

The latest rating changes

NBIX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026NeedhamReiteratedBuyBuy
Oct 12, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Sep 29, 2026UBSMaintainedBuyBuy
Sep 11, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Sep 8, 2026RBC CapitalReiteratedOutperformOutperform
Sep 3, 2026CitigroupMaintainedBuyBuy
Aug 13, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Aug 3, 2026Canaccord GenuityMaintainedBuyBuy
Aug 3, 2026Truist SecuritiesMaintainedBuyBuy
Aug 3, 2026WedbushMaintainedOutperformOutperform
Jul 31, 2026CitigroupMaintainedBuyBuy
Jul 31, 2026RBC CapitalMaintainedOutperformOutperform
Jul 31, 2026Morgan StanleyMaintainedEqual-WeightEqual-Weight
Jul 31, 2026TD CowenMaintainedBuyBuy
Jul 31, 2026Piper SandlerMaintainedOverweightOverweight
Jul 31, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Jul 31, 2026GuggenheimMaintainedBuyBuy
Jul 31, 2026StifelMaintainedBuyBuy
Jul 31, 2026NeedhamMaintainedBuyBuy
Jul 21, 2026GuggenheimMaintainedBuyBuy
Jul 17, 2026Wells FargoMaintainedOverweightOverweight
Jul 13, 2026Truist SecuritiesMaintainedBuyBuy
Jul 13, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Jul 7, 2026RBC CapitalMaintainedOutperformOutperform
Jun 30, 2026UBSMaintainedBuyBuy
May 29, 2026RBC CapitalMaintainedOutperformOutperform
May 22, 2026BernsteinInitiated—Outperform
May 8, 2026JP MorganMaintainedOverweightOverweight
May 7, 2026Truist SecuritiesMaintainedBuyBuy
May 6, 2026CitigroupMaintainedBuyBuy